GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On March29, 2018, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition for the year ended December31, 2017 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March29, 2018 (the “Press Release”), a copy of which is attached hereto as Exhibit99.1.

Except for the historical information contained in this report, the statements made by Galectin Therapeutics are forward looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Galectin Therapeutics’ future financial performance could differ significantly from the expectations of management and from results expressed or implied in the Press Release. Forward-looking statements in the Press Release are subject to certain risks and uncertainties described in the Press Release. For further information on other risk factors, please refer to the “Risk Factors” contained in Galectin Therapeutics’ Annual Report on Form10-K for the fiscal year ended December31, 2016, as filed with the Securities and Exchange Commission, and its subsequent filings with the SEC.

The information in this Item 2.02 is being furnished, not filed, to Item 2.02 of Form8-K. Accordingly, the information in Item 2.02 of this report, including the Press Release attached hereto as Exhibit99.1, will not be incorporated by reference into any registration statement filed by Galectin under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

SECTION9 — FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

-2-

GALECTIN THERAPEUTICS INC Exhibit
EX-99.1 2 d531928dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update NORCROSS,…
To view the full exhibit click here

About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.